Swayamjeet Satapathy

Swayamjeet Satapathy

Auto-generated profile, based on publicly available information

Swayamjeet Satapathy

Department of Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2023 in Thyroid®
Verified
Journal Article
Closed access
SBSanjana Ballal
Sanjana Ballal
MYMadhav Prasad Yadav
Madhav Prasad Yadav
FRFrank Roesch
Frank Roesch
SRShobhana Raju
Shobhana Raju
SSSwayamjeet Satapathy
Swayamjeet Satapathy
CBChandrasekhar Bal
Chandrasekhar Bal
Background: A theranostic probe for accurate staging and treatment is crucial for the management of medullary thyroid cancers (MTCs). The abundance of stroma in most of thyroid cancers, including MTC, opens new avenues for selecting cancer-associated fibroblasts (CAFs) as new molecular imaging and therapeutic targets. [ 68 Ga]Ga-labeled fibroblast activation protein inhibitor (FAPi) molecules have gained importance as alternative molecular imaging agents in the imaging of thyroid cancers. The purpose of this study was to compare the detection efficiency of primary and metastatic lesions of MTCs between [ 68 Ga]Ga-DOTA.SA.FAPi and [ 68 Ga]Ga-DOTANOC positron emission tomography (PET) radiotracers. Materials and Methods: In this retrospective study, [ 68 Ga]Ga-DOTANOC and [ 68 Ga]Ga-DOTA.SA.FAPi PET/CT (computed tomography) images were compared using patient-based and lesion-based analysis in patients with MTC for follow-up assessment. The quantitative assessment included comparing standardized uptake values corrected for lean body mass (SULpeak) and tumor-to-background ratios (TBR). The findings on both scans were validated with the morphological findings of the diagnostic CT. Results: Twenty-seven patients (21 males and 6 females) with a mean age of 42.4 ± 13.2 years (range 14–66 years) were included in the study. [ 68 Ga]Ga-DOTA.SA.FAPi had similar sensitivities as that of [ 68 Ga]Ga-DOTANOC PET/CT for detecting primary tumors (100% [18 of 18] vs. 94.4% [17 of 18], p = 0.979) involved lymph nodes (98.3% [118 of 120] vs. 95% [114 of 120], p = 0.288), and brain metastases (100%). [ 68 Ga]Ga-DOTA.SA.FAPi demonstrated significantly higher sensitivities than [ 68 Ga]Ga-DOTANOC PET/CT for detecting lung nodules (93.5% [87 of 93] vs. 68.9% [64 of 93], p < 0.0001), liver (100% [105 of 105] vs. 46.4% [49 of 105], p < 0.0001), bone (92.4% [110 of 119] vs. 76.5% [91 of 119], p = 0.001), and pleural metastases 98.2% versus 0%. Higher uptake values and TBR values were reported with [ 68 Ga]Ga-DOTA.SA.FAPi compared with that of [ 68 Ga]Ga-DOTANOC. Conclusion: [ 68 Ga]Ga-DOTA.SA.FAPi outperformed [ 68 Ga]Ga-DOTANOC PET/CT in the detection of distant metastases with both patient-based and lesion-based analysis in MTCs.

19 October 2022 in The Prostate
Verified
Journal Article
Closed access
SSSwayamjeet Satapathy
Swayamjeet Satapathy
CDChandan Das
Chandan Das
PAPiyush Aggarwal
Piyush Aggarwal
ASAshwani Sood
Ashwani Sood
APAshwin S. Parihar
Ashwin S. Parihar
BMBhagwant R. Mittal
Bhagwant R. Mittal

22 February 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Rahul ViswanathanRahul Viswanathan
Rahul Viswanathan
SBSanjana Ballal
Sanjana Ballal
MYMadhav P. Yadav
Madhav P. Yadav
FRFrank Roesch
Frank Roesch
Parvind SheokandParvind Sheokand
Parvind Sheokand
CBChandrasekhar Bal
Chandrasekhar Bal
Neuroendocrine tumors (NETs) are slow-growing tumors that express high levels of somatostatin receptors (SSTRs). Recent studies have shown the superiority of radiolabeled SSTR antagonists in theranostics compared to agonists. In this prospective study, we compared the diagnostic efficacy between [68Ga]Ga-DOTANOC and [68Ga]Ga-DATA5m-LM4 in the detection of primary and metastatic lesions in patients with well differentiated gastroenteropancreatic (GEP) NETs. Histologically proven GEP-NET patients underwent [68Ga]Ga-DOTANOC & [68Ga]Ga-DATA5m-LM4 PET/CT scans, which were analyzed. The qualitative analysis involved the visual judgment of radiotracer uptake validated by the morphological findings using CT, which was considered as the reference standard. Quantitative comparisons were presented as the standardized uptake value (SUV) corrected for lean body mass: SULpeak, SULavg, and tumor-to-background ratios (TBR). In total, 490 lesions were confirmed via diagnostic CT. The lesion-based sensitivity of [68Ga]Ga-DATA5m-LM4 PET/CT was 94.28% (462/490) and 83.46% (409/490) for [68Ga]Ga-DOTANOC PET/CT (p < 0.0001). [68Ga]Ga-DATA5m-LM4 had statistical significance over [68Ga]Ga-DOTANOC in liver metastases [100% vs. 89.4%; p < 0.0001 (292 vs. 253 {283 lesions on CT})] and bone metastases [100% vs. 82.9%; p = 0.005 (45 vs. 34 {41 lesions on CT})]. Statistical significance was also noted for the TBR SULpeak of the primary and liver lesions. [68Ga]Ga-DATA5m-LM4 showed better sensitivity and a higher target-to-background ratio than [68Ga]Ga-DOTANOC PET/CT. [68Ga]Ga-DATA5m-LM4 PET/CT can be used to quantify the extent of skeletal and liver metastases for better planning of SSTR agonist- or antagonist-based therapy.

7 June 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
SSSwayamjeet Satapathy
Swayamjeet Satapathy
AMAlthaf K Majeed
Althaf K Majeed
SBSanjana Ballal
Sanjana Ballal
CBChandrasekhar Bal
Chandrasekhar Bal
Background: Differentiated thyroid cancer (DTC) in young adults has been steadily rising in incidence over the decades. However, data on long-term outcomes in this specific cohort remain limited. In this study, we intended to evaluate young adults with DTC with regard to their clinical characteristics and treatment outcomes and compare the same vis-à-vis pediatric patients with DTC. Methods: Data of pediatric (≤18 years) and young adult (19-39 years) patients with DTC, from 1971 to 2016, were sequentially extracted and analyzed for clinical characteristics, treatment responses, rates of recurrent/persistent disease, and disease-free survival (DFS). Results: A total of 1803 patients with DTC were included (pediatric cohort: n = 176; young adult cohort: n = 1627). Pediatric patients with DTC had more frequent adverse baseline features including extrathyroidal extension (P = .040), nodal and distant metastases, and American Thyroid Association high-risk disease (P < .001 each). At 2 years posttreatment, young adult patients with DTC had significantly lower incomplete responses compared with pediatric patients with DTC (223/1627; 13.7% vs 94/176, 53.4%, respectively; P < .001). Over a median follow-up of 10.7 years, 120/1627 (7.4%) young adult patients with DTC had recurrent/persistent disease vs 23/176 (13.1%) pediatric patients with DTC (P = .012). The 10-year DFS probability was 93.6% for the young adult patients with DTC vs 88.7% for the pediatric patients with DTC (P = .007). American Thyroid Association high-risk disease and incomplete response at 2 years were independent predictors of significantly worse DFS in the young adult cohort (P < .001 each). Conclusions: Young adult DTCs behave less aggressively compared with their pediatric counterparts with excellent long-term outcomes. Appropriate initial and dynamic risk stratification can help optimize treatment decisions and follow-up strategies.

29 December 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AMAlthaf K Majeed
Althaf K Majeed
SSSwayamjeet Satapathy
Swayamjeet Satapathy
SBSanjana Ballal
Sanjana Ballal
CBChandrasekhar Bal
Chandrasekhar Bal
Context: The American Thyroid Association (ATA) guidelines recommend Dynamic Risk Stratification (DRS) for predicting long-term outcomes and personalizing management in adult differentiated thyroid cancers (DTCs). However, its applicability in pediatric DTCs needs to be validated. Objective: We have attempted a validation study concerning the use of DRS in pediatric DTCs. Methods: Data of children (age ≤18 years) with DTCs and follow-up of ≥5 years were extracted. All patients were classified according to DRS (excellent biochemical or structural incomplete responses). Univariate and multivariate analyses were done to identify factor(s) affecting disease-free survival (DFS). Results: We included 176 pediatric patients with DTC (median age at diagnosis 15 years). All patients underwent thyroidectomy and received radioiodine as part of initial management. On the basis of clinical, biochemical, and imaging findings acquired during the first 2 years of follow-up, the DRS system divided patients into 3 response categories: excellent response in 82/176 (46.6%), biochemical incomplete response in 56/176 (31.8%), and structural incomplete response in 38/176 (21.6%) patients. The median follow-up was 10.6 years (interquartile range 7.7-15.5). Ten-year overall survival and DFS rates were 100% and 88.7%, respectively. In univariate analysis, DFS was significantly affected by extrathyroidal extension (P = .002), lymph node metastasis (P = .018), ATA initial risk stratification (P = .033), and DRS (P = .004). However, in multivariate analysis, DRS alone showed a significant association with DFS (P = .016). Conclusion: Like adults, DRS correctly predicts long-term outcomes in pediatric DTC. In addition to ATA initial risk stratification, DRS could further refine risk in pediatric DTCs and help in planning more personalized treatment and follow-up strategies.

26 May 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SSSwayamjeet Satapathy
Swayamjeet Satapathy
PAPiyush Aggarwal
Piyush Aggarwal
ASAshwani Sood
Ashwani Sood
KCKunal R Chandekar
Kunal R Chandekar
CDChandan K Das
Chandan K Das
BMBhagwant R Mittal
Bhagwant R Mittal